Not Yet Recruiting
Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC
NCT07674524
- Conditions
- ALK Gene Mutation, ALK-positive, Bronchial Neoplasms, +16 more
- Locations
-
- Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China